Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

nual Health Care Conference, March 17-20, 2008, Boston,

Massachusetts

-- Lehman Brothers Eleventh Annual Global Healthcare Conference,

March 18-20, 2008, Miami, Florida

-- 8th Annual Fortis Biotechnology Conference, April 3, 2008, London,

England

-- 2008 Morgan Stanley Global Healthcare Unplugged Conference,

April 30-May 2, 2008, Key Biscayne, Florida

-- Deutsche Bank 33rd Annual Health Care Conference, May 5-7, 2008,

Boston, Massachusetts

-- Bank of America 2008 Health Care Conference, May 13-15, 2008, Las

Vegas, Nevada

-- Rodman & Renshaw 5th Annual Global Healthcare Conference, May 19-20,

2008, Monte Carlo, Monaco

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the significance of 2007 events and activities; expected 2008 events and activities; upcoming milestones, including the timing of the month-12 ESMB review of lorcaserin, and the importance of such milestones; the protocol, des
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... Balaton, MN (PRWEB) April 27, 2015 ... into an agreement with Texas A&M University for the ... referred to as super-intensive raceway systems. The license agreement ... Dr. Addison Lawrence, extends to countries such as China, ... United Kingdom. , “We have had inquires from ...
(Date:4/27/2015)... Diasome Pharmaceuticals, Inc. (“Diasome”) has announced ... Center (“Joslin”) to collaborate on the design of ... Directed Vesicle (“HDV”) targeting system for insulin in ... in Boston, Massachusetts, Joslin is the world's leading ... to the prevention, treatment and cure of diabetes. ...
(Date:4/27/2015)... -- Together with its customers, Elekta raised EUR 30,575 (USD ... Barcelona . The funds will be donated to ... improve cancer care, specifically radiation oncology care, around the ... should be denied potentially life-saving treatment simply because the ... and clinics around the world to take care of ...
(Date:4/27/2015)... 2015 Elsevier , a world-leading ... and Qatar University Research Office   have announced the winners ... The awards ceremony, held last week at Qatar ... by more than 40 guests representing Qatar,s ... Professor Sheikha Abdulla Al-Misnad , President of ...
Breaking Biology Technology:tru Shrimp™ Systems Acquires Global Patent for Tidal Basin™ Shrimp Production 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 2Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 4Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 5
... Nov. 29 As part of an ongoing ... maximize commercial,impact of their products, Premier Research Group ... industry-leading expertise in its core,service areas into a ... expertise within the group closely matches Premier Research,s ...
... Multi-stakeholder initiative will use health information technology ... safety efforts across,the U.S., WASHINGTON, Nov. ... announced today the formation of an innovative,research ... patients. The eHI,Connecting Communities for Drug Safety ...
... Prometheus Laboratories Inc., a,specialty pharmaceutical company ... exclusive license agreement to develop and commercialize ... North America from,Alizyme Therapeutics Limited, a wholly ... unique competitive profile based on Alizyme,s proprietary,COLAL(R) ...
Cached Biology Technology:Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research 2eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 2eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 3eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 4eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 5eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 6Prometheus Licenses COLAL-PRED(R) From Alizyme 2Prometheus Licenses COLAL-PRED(R) From Alizyme 3Prometheus Licenses COLAL-PRED(R) From Alizyme 4
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... of Toronto and the Swiss Federal Institute of Technology ... exotic plants will likely eliminate native plants growing in ... A study published in Proceedings of the National ... that invasive plants are not problematic are often based ...
... January 2013) The microbial communities that reside in the ... are an expanding area of research full of exciting discoveries ... on the most recent advances in the field, scientists and ... For Health World Summit, which is hosted this year by ...
... changed diabetes from a death sentence to a chronic ... Case Western Reserve University School of Medicine announced a ... lives of people managing diabetes. After decades of ... international group of scientists finally found a definitive answer: ...
Cached Biology News:Invading species can extinguish native plants despite recent reports 2After decades of research, scientists unlock how insulin interacts with cells 2After decades of research, scientists unlock how insulin interacts with cells 3
IgD Chain C (AMS 9.1)...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: